Ann: Update on ALA-101 and onCARlytics research collaboration, page-11

G'day Jaggin, maybe this is a rose coloured glasses thing but I actually find the disclosure quite positive and in line with the way that Baker carries himself and this company - he's a straight shooter.

First the first time ever in the history of bio-spec companies you have these guys coming out and saying we're not happy with some technical issues associated with the contract research orgs in-mouse trials and that they want the trial to be repeated. Good on them. Good quality control and good science by my read.